Document Detail

The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care - an observational analysis on non-small-cell lung cancer patients.
MedLine Citation:
PMID:  23338228     Owner:  NLM     Status:  Publisher    
PURPOSE: To evaluate frequency and severity of adverse drug reactions (ADRs) and its economic consequences after standard dose (immuno-)chemotherapy (CT) of non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Subanalysis of a prospective, multicentre, longitudinal, observational cohort study; data were collected from patient interviews and pre-planned chart reviews. Costs were aggregated per CT line and presented from provider perspective. RESULTS: A total of 120 consecutive NSCLC patients (mean age, 63.0 ± 8.4 (SD) years; men, 64.2 %; ECOG (Eastern Cooperative Oncology Group) performance status <2, 84.3 %; tumour stage III/IV, 85 %; history of comorbidity, 93.3 %) receiving 130 CT lines were evaluated. 80 % of CT lines were associated with grade 3 or 4 ADRs, 22.3 % developed potential life-threatening complications, 77.7 % were associated with at least one hospital stay (inpatient, 63.9 %; outpatient/day clinic 39.2 %, ICU 6.9 %), with a mean cumulative number of 12.8 (±14.0 SD) hospital days. Mean (median) toxicity management costs per CT line (TMC-TL) amounted to <euro>3,366 (<euro>1,406) and were found to be higher for first-line compared to second-line treatment: <euro>3,677 (<euro>1,599) vs. <euro>2,475 (<euro>518). TMC-TL were particularly high in CT lines with ICU care <euro>12,207 (<euro>9,960). Eight out of 11 ICU stays were associated with grade 3 or 4 infections. Nine CT lines with ICU care accounted for 25 % of total expenses (<euro>109,861 out of <euro>437,580). CONCLUSIONS: In first-line NSCLC treatment, in particular, CT toxicity management is expensive. Asymmetric cost distribution seems to be triggered by infection associated ICU care. Its avoidance should reduce patients' clinical burden and have considerable economic implications. Nevertheless, comparative observational studies have to confirm estimated savings.
Angela Ihbe-Heffinger; B Paessens; K Berger; M Shlaen; R Bernard; C von Schilling; C Peschel
Related Documents :
6224898 - Management of functional disability in homebound patients.
8480018 - Is there consensus on the placement of older adults?
23305188 - Palliative care provision in the emergency department: barriers reported by emergency p...
16131628 - Reconsidering substitution in long-term care: when does assistive technology take the p...
23114978 - Management of pulmonary hypertension in neonates with congenital diaphragmatic hernia.
11231108 - A statistical design to evaluate the influence of manufacturing factors on the material...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-23
Journal Detail:
Title:  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer     Volume:  -     ISSN:  1433-7339     ISO Abbreviation:  Support Care Cancer     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9302957     Medline TA:  Support Care Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Hospital Pharmacy Department, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Germany,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The association of serum prolidase activity with developmental dysplasia of the hip.
Next Document:  Predictive factors for overall quality of life in patients with advanced cancer.